Tramontane Therapeutics, a company aiming on developing treatments for highly prevalent diseases with its own production system to foster clinical development

Tramontane Therapeutics is a gene therapy company focused on successfully developing a compelling portfolio of innovative genetic treatments for highly prevalent diseases affecting large populations of patients, including neurodegenerative and metabolic disorders.

The primary value position of Tramontane Therapeutics is in the field of metabolic diseases, such as Non-alcoholic steatohepatitis (NASH), Type 2 diabetes, Obesity and the behavioral deficits and cognitive decline associated with diabetes and obesity.

Tramontane Therapeutics portfolio also includes investigational gene therapies for neurodegenerative diseases such as Alzheimer’s disease (AD). Other preclinical programs in the neurological pipeline include investigational gene therapies for Parkinson disease (PD) and other central disorders associated with impaired cognition and behaviour.

The pioneering genetic medicines developed at Tramontane Therapeutics for the treatment of neurodegenerative and metabolic diseases are based on non- pathogenic adeno-associated viral (AAV) vectors to express the therapeutic proteins of interest in the Central Nervous System (CNS) or the periphery.

Tramontane Therapeutics is developing a GMP AAV Manufacturing Plant to bring its products to the clinic and to the market based on our own wide experience and IP protected AAV production processes.